长效卡博特韦/利匹韦林注射后短暂系统性不良反应:5年队列研究
这项法国单中心前瞻性5年队列纳入308名接受长效卡博特韦/利匹韦林注射的HIV感染者,共监测4,644次注射。 transient immediate systemic side effects(TISSE)发生率为每注射0.60%(95%CI 0.40-0.87%),以剧烈腰痛和呼吸困难为主,均在15分钟内缓解,未增加停药。部分事件后利匹韦林和/或卡博特韦血药浓度显著升高。
要点
- TISSE发生率低(0.60%/注射),症状短暂自限,但临床表现突出。
- 主要表现为剧烈腰痛和呼吸困难/胸部压迫感,可模仿心血管急症。
- 治疗持续率未受影响,但需识别症状以避免误判。
核心结论
- TISSE短暂自限但临床显著,可能模仿心血管急症。
- 事件后血药浓度升高提示药物无意进入体循环,以利匹韦林为主,但未确立因果关系。
研究设计与样本
- 前瞻性单中心法国队列,2021-2026年纳入308名接受CAB-RPV-LA的HIV成人,监测4,644次注射。
主要发现
- 24人发生28次TISSE,每注射0.60%(95%CI 0.40-0.87%)。
- 症状以剧烈腰痛(18次)和呼吸困难/胸部压迫感(16次)为主,7次并存。
- 全部症状15分钟内缓解,无需住院。
- 停药率无差异(2/24 vs 38/284,Fisher精确检验p=0.75)。
- 17次采样事件中利匹韦林和/或卡博特韦浓度显著升高,利匹韦林升高14次(最高达谷浓度上限767倍),卡博特韦升高4次。
临床怎么用
- 医护人员应熟悉TISSE临床表现,识别其短暂自限性,避免误判为心血管急症。
局限性
- 单中心研究,TISSE为护士前瞻性记录,可能漏报。
- 浓度比较采用匹配对照,未确立因果关系。
- 卡博特韦参与仅为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterise transient immediate systemic side effects (TISSE) following long-acting cabotegravir/rilpivirine (CAB-RPV-LA) injections, estimate their incidence, assess treatment continuation, and investigate associated plasma drug concentrations. METHODS: This prospective single-centre French cohort included adults with HIV receiving CAB-RPV-LA during 2021-2026. Nurses prospectively documented unexpected systemic symptoms. Treatment discontinuation was compared by TISSE status. Plasma concentrations were measured by LC-MS/MS after TISSE events and compared with post-injection concentrations in 24 matched asymptomatic controls and routine trough measurements. RESULTS: Among 308 participants receiving 4,644 monitored on-site injection sessions, 24 experienced 28 TISSE episodes: 0.60% per session (exact Poisson 95% CI, 0.40-0.87%). Symptoms occurred during or shortly after injection, predominantly intense lumbar pain (18 episodes) and dyspnea/chest oppression (16), co-occurring in seven. All symptoms resolved within 15 minutes; none required hospitalisation. No difference in treatment discontinuation was detected (2/24 versus 38/284; Fisher's exact test, p=0.75). In all 17 sampled episodes, RPV and/or CAB concentrations were markedly elevated. RPV elevations occurred in 14 episodes, (up to 767-fold the upper concentration bound at trough), and CAB elevations in four, including one involving both drugs. CONCLUSIONS: TISSE episodes were brief and self-limited but clinically striking, potentially mimicking cardiovascular emergencies. Post-event concentration elevations suggest inadvertent systemic passage, predominantly involving RPV, without establishing causality. Possible CAB involvement remains exploratory. Recognising TISSE is important, and healthcare professionals should be familiar with its clinical presentation. TRIAL REGISTRATION: NCT02898987.
引用
- Hocqueloux L, Pires Roteia D, Pallay S, et al. Transient immediate systemic side effects following long-acting cabotegravir and rilpivirine injections in people with HIV: a 5-year cohort study. Clin Microbiol Infect. 2026. PMID: 42951107. doi:10.1016/j.cmi.2026.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。